With Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk – STAT

In order to approve a new Alzheimer’s treatment, the Food and Drug Administration is rewriting its rulebook, an enormously risky move that could accelerate the public’s access to medicines but upend … [+1645 chars]

View The Article On: STAT

Powered By

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top